近日,弘星相和(太仓)生物科技有限公司(下文简称“弘星相和”)宣布完成近亿元人民币Pre-A轮融资。本轮融资由北极光创投领投,东卫基金、DCG Holdings、鼎赋投资、未来启创基金跟投,天使轮股东星药太浩基金持续加码。公司表示,本轮融资资金将主要用于丰富并推进现有管线的临床前及临床POC研究, 同时全面布局AI平台、生物类器官平台在药物研发与评价中的应用,着力于靶点和分子成药性评估、分子和试验...
Source Link近日,弘星相和(太仓)生物科技有限公司(下文简称“弘星相和”)宣布完成近亿元人民币Pre-A轮融资。本轮融资由北极光创投领投,东卫基金、DCG Holdings、鼎赋投资、未来启创基金跟投,天使轮股东星药太浩基金持续加码。公司表示,本轮融资资金将主要用于丰富并推进现有管线的临床前及临床POC研究, 同时全面布局AI平台、生物类器官平台在药物研发与评价中的应用,着力于靶点和分子成药性评估、分子和试验...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.